(Q38087939)

28 August 2017

title

Current approaches for the treatment of multiple myeloma (English)

1 reference

28 August 2017

Reiko Watanabe

1

1 reference

28 August 2017

Michihide Tokuhira

series ordinal

2

1 reference

28 August 2017

Masahiro Kizaki

series ordinal

3

1 reference

28 August 2017

publication date

10 March 2013

1 reference

International Journal of Hematology

28 August 2017

published in

1 reference

28 August 2017

volume

97

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

333-344

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

28 August 2017

1 reference

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Update on risk stratification and treatment of newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

IMWG consensus on maintenance therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Adverse effects of thalidomide administration in patients with neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Novel therapies in MM: from the aspect of preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1294-Z

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

21 January 2018

1 reference

12 December 2020

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

12 December 2020

Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives

1 reference

12 December 2020

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

12 December 2020

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

1 reference

12 December 2020

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

12 December 2020

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

1 reference

12 December 2020

The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies

1 reference

12 December 2020

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

12 December 2020

High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial

1 reference

12 December 2020

An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

1 reference

12 December 2020

"Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?"

1 reference

12 December 2020

10.1007/S12185-013-1294-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1029789303

0 references

1 reference